1 NOVEMBER 2019
EU PROJECT - ERA4TB - European Regimen Accelerator for Tuberculosis
Our institute is participating to a European consortium focusing on tuberculosis
Status: Active Start: Jan/2020 - End: Dec/2025
The ERA4TB project has received funding from the European Union’s IMI 2 Joint Undertaking (JU) under grant agreement No 853989.
The main objective of ERA4TB is to create a European open platform to accelerate the development of new regimens for the treatment of tuberculosis.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989.
The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.